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(CN) cm -1 ; 1 H NMR (DMSO-d6, 300 MHz) δ 4.14 (dd, 1H, J = 5.6 Hz, J = 16.1 Hz), 4.22 (dd, 11-Amino-2-(hydroxymethyl)-12-phenyl-7,9,10,12-tetrahydropyrano [2',3':5,6 ]pyrano [2,3-b] quinolin-4(8H)-one (2a). Following the general method, the reaction of compound 1a [4] (0.5 g, 1.6 mmol) in 1,4-dioxane (30 mL) with cyclohexanone (0.23 g, 2.4 mmol) and AlCl3 (0.31 g, 2.4 mmol), after 2 h, gave product 2a (0.51 g, 77 %): mp ˃ 260 °C; IR (KBr) n 3468 (OH), 5.36; N, 7.44. Found: C, 70.67; H, 5.22; N, 7.38 .
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11-Amino-2-(hydroxymethyl)-12-(p-tolyl)-7,9,10,12-tetrahydropyrano [2',3':5,6 ]pyrano [2,3-b] quinolin-4(8H)-one (2b) : Following the general method, the reaction of compound 1b [2] 11-Amino-2-(hydroxymethyl)-12-(2-methoxyphenyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano [2,3-b] , 5.46; N, 6.89. Found: C, 68.21; H, 5.55 ; N, 6.81.
pyrano [2,3-b] 11-Amino-2-(hydroxymethyl)-12-(4-methoxyphenyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano [2,3-b] quinolin-4(8H)-one (2e). Following the general method, the reaction of compound 1e [3] (0.8 g, 2 mmol) in 1,4-dioxane (30 mL) with cyclohexanone (0.37 g, 3 mmol) and AlCl3 (0.43 g, 3 mmol), after 2 h, afforded product 2e (0.51 g, 52%): mp ˃260 °C; IR (KBr) 11-Amino-12-(3-fluorophenyl)-2-(hydroxymethyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano [2,3-b] quinolin-4(8H)-one (2g). Following the general method, the reaction of compound 1g [4] 11-Amino-12-(2-chlorophenyl)-2-(hydroxymethyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano [2,3-b] , 4.21; N, 6.15. Found: C, 58.30; H, 4.28; N, 6.19. 11-Amino-12-(2,6-dichlorophenyl)-2-(hydroxymethyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano [2,3-b] 
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6. ADME of compounds KT2a-l properties of both enantiomers of tacrine derivatives KT2a-l were accomplished using the QikProp module of Schrodinger suite (QikProp, version 3.8, Schrodinger, LLC, New York, NY, 2013) running in normal mode, for assessing the druggability. Drug kinetics and exposure of tissues to drug influences the pharmacological activity and the performance of a drug, which is ultimately determined by its ADME properties. Nearly 45 physically significant descriptors and pharmacologically relevant properties were predicted and investigated (Table S1 ). The results suggest that the compounds do not violate Lipinski's rule (0). Almost all calculated descriptors and properties except the estimated number of hydrogen bonds that would be donated by the solute (acceptHB) are within the expected thresholds. Aqueous solubility (QPlogS) of organic molecules plays a key impact on many ADME-related properties. All compounds showed solubility values within the limits. The partition coefficient (QPlogPo/w), critical for estimation of absorption within the body, ranged between -2.56 and 3.30 (Table S1 ).
Among all the properties, the predicted value for the Blood Brain Barrier (BBB) penetration (QPlogBB: acceptable range −3.0 to 1.2) is a very important parameter, indicating the ability of the molecule to pass through the blood brain barrier, which is mandatory for Alzheimer's treatment. The predicted logBB values for compounds KT2a-l (Table S1) (Table S1 ). Other physicochemical descriptors obtained by QikProp (Table   S1 ) are within the acceptable scope for human use, thus making these derivatives as suitable drug candidates and possible CNS drug.
